Introduction
Multiple myeloma, a cancer originating in the bone marrow's plasma cells, presents a significant area of focus in health and medical advancements. Plasma cells are a crucial component of the immune system, responsible for producing antibodies that combat infections. In multiple myeloma, these plasma cells become cancerous and proliferate uncontrollably within the bone marrow. This accumulation of malignant cells disrupts the production of normal blood cells and leads to various complications. Understanding this disease is vital as it not only impacts individual health but also drives ongoing research into novel therapies and diagnostic techniques. The medical community's continuous efforts have led to significant improvements in the prognosis for individuals diagnosed with multiple myeloma.
What is Multiple Myeloma?
Multiple myeloma is fundamentally a cancer of plasma cells, which reside in the bone marrow. These normal plasma cells are integral to the body's defense system. Their primary function is to create antibodies, also known as immunoglobulins, which identify and attack harmful germs, thereby protecting the body from infections. When plasma cells become cancerous, this delicate balance is disrupted.
The development of multiple myeloma begins with a single, abnormal plasma cell within the bone marrow. This cell undergoes genetic changes that cause it to multiply rapidly and without the normal controls that regulate cell growth and death. Unlike healthy cells, these cancerous plasma cells do not mature and die at a programmed rate; instead, they accumulate in the bone marrow. This overgrowth leads to a situation where the cancerous cells crowd out the healthy blood-forming cells, including red blood cells, white blood cells, and platelets. This "crowding out" effect is a primary reason why individuals with multiple myeloma often experience complications such as anemia (low red blood cell count) and an increased susceptibility to infections.
A key characteristic of multiple myeloma is the production of abnormal antibodies by the cancerous plasma cells. These abnormal proteins are called monoclonal proteins, or M proteins. They are also known by other names, including M-spike, paraprotein, and, when found in urine, Bence Jones proteins. Unlike the antibodies produced by healthy plasma cells, these M proteins do not effectively fight infections. Instead, they can build up in the body and cause various problems, including damage to the kidneys. The accumulation of these non-functional proteins highlights the systemic impact of multiple myeloma beyond the bone marrow.
Multiple myeloma often develops from precursor conditions known as Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM). MGUS is characterized by the presence of low levels of M proteins in the blood that do not cause any damage to the body. It is a relatively common condition, particularly in older adults, and while most people with MGUS will never develop multiple myeloma, it does increase the risk. SMM represents an earlier stage of myeloma where individuals have higher levels of M proteins or cancerous plasma cells than in MGUS, but they do not experience the symptoms or organ damage associated with active multiple myeloma. Often referred to as asymptomatic myeloma, SMM typically does not require immediate treatment but necessitates careful monitoring to detect any signs of progression to active myeloma. The existence of these precursor conditions suggests a potential opportunity for early detection and intervention strategies, although widespread screening is not yet standard practice and remains an area of active research.
Causes and Risk Factors of Multiple Myeloma
While significant progress has been made in understanding multiple myeloma, the precise cause of the disease remains unclear. It is understood that the disease initiates with a genetic mutation in a single plasma cell within the bone marrow. This initial mutation leads to the uncontrolled proliferation of the abnormal cell and its descendants.
Despite the lack of a definitive cause, several risk factors have been identified that can increase an individual's likelihood of developing multiple myeloma. One of the most significant risk factors is age, with the majority of diagnoses occurring in individuals in their late 60s. This strong correlation with age suggests that accumulated genetic damage over time may play a role in the transformation of a normal plasma cell into a cancerous one. The increased risk with age aligns with the general understanding of cancer development, where the likelihood of cellular mutations increases over a person's lifespan.
Gender also appears to play a role, as men are more likely to develop multiple myeloma than women. The reasons behind this gender disparity are not fully understood and warrant further research into potential hormonal or genetic factors that may contribute to this difference.
Race is another notable risk factor. Black individuals have a higher incidence of multiple myeloma compared to people of other races. Notably, research indicates that Black individuals tend to develop myeloma approximately 10 years earlier than white individuals. This significant racial disparity underscores the need for further investigation into genetic or environmental factors that may be more prevalent within the Black population.
Having a family history of multiple myeloma also increases the risk of developing the disease. If a sibling or parent has been diagnosed with multiple myeloma, an individual's risk is elevated, suggesting a potential genetic predisposition to the condition. While not directly causative in most cases, shared genetic factors within families may increase susceptibility.
Finally, a personal history of MGUS is a well-established risk factor for multiple myeloma. As myeloma often develops from this precursor condition, individuals with MGUS are at a higher risk and require ongoing monitoring. The progression from MGUS to myeloma is a critical area of research aimed at understanding the triggers that facilitate this transition. It is important to remember that while these risk factors are associated with an increased likelihood of developing multiple myeloma, their presence does not guarantee that the disease will occur. Furthermore, there is currently no known way to prevent multiple myeloma, and individuals who develop the condition did nothing to cause it.
How Multiple Myeloma Affects the Body
Multiple myeloma exerts its effects on the body through various mechanisms, primarily by disrupting normal bone marrow function and producing abnormal proteins.
One of the most significant impacts of multiple myeloma is on bone health. Myeloma cells interfere with the normal balance between osteoclasts (cells that break down old bone) and osteoblasts (cells that build new bone). Specifically, myeloma cells produce substances that accelerate the activity of osteoclasts, leading to an increased breakdown of bone tissue without sufficient new bone formation. This imbalance results in bone weakening, pain, and an increased risk of fractures. Bone pain is a common symptom, often localized in the back, ribs, and hips. The weakened bones are also prone to pathological fractures, which occur due to the underlying disease rather than significant injury, and the formation of lytic lesions, which are holes in the bones that can be visible on imaging studies. The bone damage caused by myeloma is a major source of morbidity, leading to chronic pain, fractures, and potential complications such as spinal cord compression if the bones in the spine weaken and collapse.
Kidney function is also commonly affected by multiple myeloma. The abnormal M proteins produced by myeloma cells can accumulate in the kidneys, damaging their filtering units. Additionally, the increased bone breakdown can lead to high levels of calcium in the blood (hypercalcemia), which can also impair kidney function. In some cases, this damage can progress to kidney failure. Early kidney problems may not present with noticeable symptoms, but they can often be detected through blood and urine tests. As kidney function declines, individuals may experience symptoms such as leg swelling, shortness of breath, and itching. The potential for kidney dysfunction underscores the importance of regular monitoring in individuals with multiple myeloma.
The immune system is significantly compromised in multiple myeloma. The overgrowth of cancerous plasma cells in the bone marrow crowds out the normal white blood cells that are essential for fighting infections. Furthermore, the abnormal plasma cells produce non-functional antibodies (M proteins) that cannot effectively combat pathogens. As a result, individuals with multiple myeloma are at an increased risk of developing various infections, including pneumonia, bladder and kidney infections, sinusitis, and skin infections. This heightened susceptibility to infections necessitates proactive strategies for prevention and prompt management.
In addition to the effects on bones, kidneys, and the immune system, multiple myeloma can lead to other complications. Anemia, a low red blood cell count, is common due to the crowding of the bone marrow by myeloma cells, resulting in fatigue and shortness of breath. Hypercalcemia, or high blood calcium levels, occurs as bone breaks down, releasing calcium into the bloodstream. This can cause symptoms such as increased thirst, frequent urination, nausea, constipation, and confusion. In some individuals, high levels of M proteins can cause the blood to thicken, a condition known as hyperviscosity. This can slow blood flow to the brain, leading to symptoms like confusion, dizziness, and even stroke-like symptoms, requiring immediate medical attention.
Symptoms and Diagnosis of Multiple Myeloma
The symptoms of multiple myeloma can vary significantly from person to person, and in the early stages, some individuals may not experience any noticeable signs. When symptoms do arise, they can be diverse and affect multiple body systems.
Common symptoms associated with multiple myeloma include persistent bone pain, particularly in the back, ribs, or hips; fatigue that is often severe and unexplained; general weakness; shortness of breath, often related to anemia; frequent infections; unexplained weight loss; nausea; constipation; loss of appetite; and mental fogginess or confusion. Individuals may also experience increased thirst and frequent urination, which can be signs of high calcium levels or kidney problems. Easy bruising or bleeding can occur due to a low platelet count, and swelling in the legs may indicate kidney dysfunction.
Early warning signs of multiple myeloma can be subtle and are not always specific to the disease. However, certain signs should prompt medical evaluation:
- Persistent bone pain, especially in the back or ribs.
- Unexplained fractures occurring with minimal or no injury.
- Unusual and persistent fatigue or weakness that is not relieved by rest.
- Recurrent infections that are frequent or severe.
- Easy bruising or bleeding without a clear cause.
- Excessive thirst and frequent urination, which could indicate high calcium levels.
- Numbness or weakness in the limbs, potentially due to nerve compression or hyperviscosity.
- New onset of confusion or altered mental state.
It is crucial to remember that these symptoms can also be caused by various other medical conditions. Therefore, if any of these signs are present, it is essential to consult a healthcare professional for a thorough evaluation and accurate diagnosis.
The diagnosis of multiple myeloma typically involves a combination of several types of tests. Blood tests are often the first step in the diagnostic process. These tests can detect the presence of M proteins and another protein called beta-2-microglobulin, both of which are produced by myeloma cells. Additionally, blood tests can provide valuable information about kidney function, blood cell counts, calcium levels, and uric acid levels, offering clues to the healthcare team about a potential diagnosis. The detection of an elevated protein level in routine blood work can be an initial indicator that warrants further investigation for multiple myeloma.
Urine tests are another important diagnostic tool. They can detect M proteins that are excreted in the urine, where they are known as Bence Jones proteins.
A bone marrow biopsy and aspiration are often necessary to confirm a diagnosis of multiple myeloma. This procedure involves taking small samples of bone marrow, usually from the hip bone, using thin needles. The samples are then examined in a laboratory to count the percentage of plasma cells and look for abnormal myeloma cells. A clonal plasma cell count of 10% or greater in the bone marrow is a significant criterion for diagnosing multiple myeloma. Specialized tests, such as fluorescence in situ hybridization (FISH), may also be performed on the bone marrow samples to identify specific genetic changes within the myeloma cells, which can have implications for prognosis and treatment. Bone marrow biopsy is considered the definitive diagnostic test, providing direct evidence of the presence and characteristics of cancerous plasma cells.
Imaging tests play a crucial role in assessing the extent of bone damage associated with multiple myeloma. These tests may include X-rays, MRI scans, CT scans, and positron emission tomography (PET) scans. They help in identifying areas of bone thinning (osteoporosis) and the presence of lytic lesions, which are characteristic of myeloma. PET scans can be particularly useful in locating areas of active cancer growth within the body. The information gathered from these diagnostic tests helps the healthcare team determine the stage of the myeloma, which typically ranges from 1 to 3, indicating the aggressiveness of the disease. Additionally, a risk level may be assigned to further characterize the myeloma's behavior. This staging and risk assessment are essential for understanding the prognosis and planning the most appropriate treatment strategy.
Table 1: Common Symptoms of Multiple Myeloma
| Category | Symptoms |
|---|---|
| Skeletal | Bone pain (back, ribs, hips), unexplained fractures, bone weakness |
| Blood-related | Fatigue, weakness, shortness of breath (anemia), easy bruising or bleeding (low platelets), frequent infections (low white blood cells) |
| Renal | Increased thirst, frequent urination, leg swelling |
| Neurological | Mental fogginess or confusion, numbness or weakness in limbs |
| General | Unexplained weight loss, nausea, constipation, loss of appetite |
Navigating the Treatment Landscape for Multiple Myeloma
The approach to treating multiple myeloma is not always immediate, especially for individuals diagnosed with smoldering myeloma who are not yet experiencing symptoms. In such cases, a strategy of watchful waiting with regular monitoring may be adopted. However, when multiple myeloma becomes active and causes symptoms, treatment is initiated with the primary goals of relieving pain, controlling complications, and slowing down the growth of myeloma cells. The treatment landscape for multiple myeloma is complex and involves various modalities.
Chemotherapy remains a cornerstone of myeloma treatment. It utilizes strong medications to kill cancer cells by targeting their rapid growth. Common chemotherapy drugs used in the treatment of multiple myeloma include melphalan, cyclophosphamide, doxorubicin, and bortezomib (which is also classified as a proteasome inhibitor). While effective in killing myeloma cells, chemotherapy can also affect healthy, rapidly dividing cells, leading to various side effects such as fatigue, nausea, hair loss, an increased risk of infection, mouth sores, and a loss of appetite. Low blood counts are also a common side effect. Despite these side effects, chemotherapy can be highly effective in reducing the number of myeloma cells and achieving remission, often used in combination with other therapies to enhance its efficacy.
Stem cell transplantation is another critical treatment option for many individuals with multiple myeloma. This procedure involves replacing diseased bone marrow with healthy bone marrow. The most common type of transplant for myeloma is an autologous transplant, where the patient's own stem cells are collected from their blood. Following high-dose chemotherapy to destroy the diseased bone marrow, the collected healthy stem cells are infused back into the patient's body, where they can then rebuild the bone marrow. While less common, allogeneic transplants, using stem cells from a donor, may be considered in certain situations. Stem cell transplantation allows for the use of very high doses of chemotherapy that would otherwise be intolerable, potentially leading to prolonged remission and improved survival for eligible patients. However, it is associated with significant risks and side effects, including the risk of infection, low blood counts, fatigue, nausea, and, in the case of allogeneic transplant, graft-versus-host disease. It is important to note that while stem cell transplant can be very effective, it is not typically a cure for multiple myeloma.
Targeted therapy represents a significant advancement in myeloma treatment. These drugs work by attacking specific chemicals or pathways within cancer cells, aiming to disrupt their growth and survival. Examples of targeted therapies used in myeloma include proteasome inhibitors such as bortezomib, carfilzomib, and ixazomib; immunomodulatory drugs (IMiDs) like thalidomide, lenalidomide, and pomalidomide; monoclonal antibodies such as daratumumab and elotuzumab; and BCL2 inhibitors like venetoclax. Proteasome inhibitors work by blocking the action of proteasomes, which are involved in protein degradation within cells, leading to a buildup of proteins that can cause cancer cell death. IMiDs have multiple mechanisms of action, including stimulating the immune system and directly inhibiting myeloma cell growth. Monoclonal antibodies are designed to recognize and bind to specific proteins on the surface of myeloma cells, marking them for destruction by the immune system or directly inhibiting their growth. BCL2 inhibitors block a protein that helps cancer cells survive, making them more susceptible to other anticancer drugs. Targeted therapies offer a more precise approach to treating myeloma, potentially resulting in fewer side effects compared to traditional chemotherapy.
Immunotherapy is another revolutionary approach that harnesses the body's own immune system to fight cancer cells. Various forms of immunotherapy are used in myeloma, including immunomodulatory drugs (IMiDs), monoclonal antibodies, CAR-T cell therapy, and bispecific antibodies (BiTEs). CAR-T cell therapy involves modifying a patient's T cells (a type of immune cell) to express a chimeric antigen receptor (CAR) that specifically recognizes and attacks myeloma cells. These modified T cells are then infused back into the patient. Bispecific antibodies are designed to bind to both a myeloma cell and a T cell, bringing them together to facilitate the destruction of the cancer cell by the immune system. Immunotherapy has shown remarkable success in treating relapsed or refractory myeloma, where other treatments have failed.
Radiation therapy uses high-energy beams to kill cancer cells in a localized area. In multiple myeloma, it is primarily used to treat painful bone lesions or localized tumors called plasmacytomas. Potential side effects of radiation therapy include skin changes in the treated area and fatigue.
Corticosteroids, such as dexamethasone and prednisone, are also commonly used in the treatment of multiple myeloma. These medications help to control inflammation in the body and also have direct anti-myeloma effects.
Table 2: Overview of Multiple Myeloma Treatment Options
| Treatment Option | Mechanism of Action | Examples |
|---|---|---|
| Chemotherapy | Kills rapidly dividing cells, including myeloma cells. | Melphalan, Cyclophosphamide, Doxorubicin |
| Stem Cell Transplant | Replaces diseased bone marrow with healthy stem cells, often after high-dose chemotherapy. | Autologous Stem Cell Transplant, Allogeneic Stem Cell Transplant |
| Targeted Therapy | Attacks specific molecules or pathways involved in cancer cell growth and survival. | Bortezomib (Proteasome Inhibitor), Lenalidomide (IMiD), Daratumumab (Monoclonal Antibody), Venetoclax (BCL2 Inhibitor) |
| Immunotherapy | Enhances the body's immune system to fight cancer cells. | Lenalidomide (IMiD), Daratumumab (Monoclonal Antibody), CAR-T Cell Therapy, Bispecific Antibodies |
| Radiation Therapy | Uses high-energy rays to kill cancer cells in a localized | External Beam Radiation Therapy |
| Corticosteroids | Reduce inflammation and have direct anti-myeloma effects. | Dexamethasone, Prednisone |
Table 3: Five-Year Relative Survival Rates for Multiple Myeloma by Stage
| SEER Stage | 5-Year Relative Survival Rate |
|---|---|
| Localized (Solitary Plasmacytoma) | 80% |
| Distant (Multiple Myeloma) | 60% |
| All SEER Stages Combined | 62% |
| R-ISS Stage | 5-Year Relative Survival Rate | Median Survival Time |
|---|---|---|
| Stage 1 | ~80% | 62 months |
| Stage 2 | ~62% | 44 months |
| Stage 3 | ~40% | 29 months |
Note: Survival rates are estimates based on data from past years and may not reflect the most recent advancements in treatment. Individual outcomes can vary.
Living Well with Multiple Myeloma: Advice and Resources
Living with multiple myeloma requires a multifaceted approach that addresses not only the physical aspects of the disease but also the emotional and practical challenges it presents. Making positive lifestyle adjustments can significantly impact a patient's well-being. Maintaining a healthy diet with regular, small meals and incorporating exercise, guided by a physical therapist, can help manage energy levels and maintain strength. Strategies for managing fatigue, such as ensuring adequate rest and pacing activities, are crucial. Pain management, often involving consultation with healthcare professionals and pain specialists, is also an essential component of living well with myeloma.
The emotional toll of a multiple myeloma diagnosis can be significant, making mental health support paramount. Coping strategies such as open communication with family and friends, participation in support groups, and the use of mindfulness and relaxation techniques can be beneficial. Seeking professional counseling from therapists or oncology social workers can provide valuable emotional support and guidance. Resources like CancerCare and the Cancer Support Community offer various forms of mental health support, including counseling and support groups.
Connecting with patient resources and advocacy groups can provide invaluable information, support, and a sense of community. Organizations such as the International Myeloma Foundation (IMF), the Multiple Myeloma Research Foundation (MMRF), and The Leukemia & Lymphoma Society (LLS) offer a wide range of resources, including educational materials, support groups, and information about the latest research and treatment options. Patient advocacy groups also play a crucial role in raising awareness, supporting research funding, and advocating for improved care for individuals living with multiple myeloma.
Latest Research and Advancements in Multiple Myeloma
The field of multiple myeloma research is dynamic and constantly evolving, leading to the development of new therapies and improved outcomes for patients. Clinical trials are essential for testing the safety and effectiveness of these emerging treatments.
Recent breakthroughs in myeloma treatment include significant advancements in immunotherapy. CAR-T cell therapy, where a patient's own immune cells are engineered to target myeloma cells, has shown remarkable results in some individuals with relapsed or refractory disease. Bispecific antibodies, another form of immunotherapy, are also demonstrating promise in clinical trials. The development of new monoclonal antibodies, such as daratumumab (Darzalex Faspro) and isatuximab (Sarclisa), and their approval for use in newly diagnosed patients, have further expanded treatment options and improved outcomes. Notably, these four-drug regimens have shown increased rates of patients achieving minimal residual disease (MRD) negativity, a state where highly sensitive tests cannot detect any myeloma cells, which is associated with improved survival. Advancements in stem cell transplantation techniques, such as the use of drugs like motixafortide to enhance stem cell collection, are also contributing to better outcomes. The focus on achieving MRD negativity has become an important goal in myeloma treatment, reflecting the increasing sensitivity of detection methods and the potential for deeper and more durable responses. Research continues to explore new targeted therapies and the next generation of immunomodulating drugs, offering hope for even more effective treatments in the future.
While multiple myeloma is currently considered incurable, the progress made in research and treatment has significantly improved survival rates and the quality of life for individuals living with the disease. The ongoing dedication of researchers and clinicians to finding a cure and developing even more effective therapies offers continued hope for the future.
Conclusion
Multiple myeloma is a complex cancer of plasma cells that affects the bone marrow and can lead to a range of complications impacting bone health, kidney function, and the immune system. Understanding the disease, its symptoms, and the available diagnostic methods is crucial for early detection and effective management. The treatment landscape for multiple myeloma has evolved significantly, with a variety of options including chemotherapy, stem cell transplantation, targeted therapy, and immunotherapy offering improved outcomes and prolonged survival for many patients. Living well with multiple myeloma involves making positive lifestyle adjustments, seeking mental health support, and connecting with valuable patient resources and advocacy groups. The ongoing research and development of emerging therapies continue to provide hope for further advancements and, ultimately, a cure for this challenging disease. The progress made in recent years underscores the commitment of the medical community to improving the lives of individuals affected by multiple myeloma.
Works cited
- www.mayoclinic.org, accessed March 31, 2025, https://www.mayoclinic.org/diseases-conditions/multiple-myeloma/symptoms-causes/syc-20353378#:~:text=Multiple%20myeloma%20is%20a%20cancer,build%20up%20in%20bone%20marrow.
- Multiple myeloma - Symptoms and causes - Mayo Clinic, accessed March 31, 2025, https://www.mayoclinic.org/diseases-conditions/multiple-myeloma/symptoms-causes/syc-20353378
- What Is Multiple Myeloma? | American Cancer Society, accessed March 31, 2025, https://www.cancer.org/cancer/types/multiple-myeloma/about/what-is-multiple-myeloma.html
- Multiple Myeloma - Symptoms & Causes - MD Anderson Cancer Center, accessed March 31, 2025, https://www.mdanderson.org/cancer-types/multiple-myeloma.html
- Multiple Myeloma - StatPearls - NCBI Bookshelf, accessed March 31, 2025, https://www.ncbi.nlm.nih.gov/books/NBK534764/
- Multiple myeloma: Its evolution, treatment and the quest to catch it early, accessed March 31, 2025, https://cancerblog.mayoclinic.org/2025/03/18/multiple-myeloma-its-evolution-treatment-and-the-quest-to-catch-it-early/
- 9 Q&A about multiple myeloma - Mayo Clinic Health System, accessed March 31, 2025, https://www.mayoclinichealthsystem.org/hometown-health/speaking-of-health/9-q-and-a-about-multiple-myeloma
- Mayo Clinic Minute: What is multiple myeloma?, accessed March 31, 2025, https://newsnetwork.mayoclinic.org/discussion/3-22-mayo-clinic-minute-what-is-multiple-myeloma/
- What is Multiple Myeloma? Symptoms, Causes, & Prognosis, accessed March 31, 2025, https://themmrf.org/multiple-myeloma/
- Multiple myeloma - Diagnosis and treatment - Mayo Clinic, accessed March 31, 2025, https://www.mayoclinic.org/diseases-conditions/multiple-myeloma/diagnosis-treatment/drc-20353383
- Signs and Symptoms of Multiple Myeloma | American Cancer Society, accessed March 31, 2025, https://www.cancer.org/cancer/types/multiple-myeloma/detection-diagnosis-staging/signs-symptoms.html
- Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment - NCI, accessed March 31, 2025, https://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq
- If You Have Multiple Myeloma | American Cancer Society, accessed March 31, 2025, https://www.cancer.org/cancer/types/multiple-myeloma/if-you-have-multiple-myeloma.html
- Multiple myeloma - Mayo Clinic, accessed March 31, 2025, https://www.mayoclinic.org/diseases-conditions/multiple-myeloma/multimedia/multiple-myeloma/img-20008071
- Multiple Myeloma Treatment Options - Virginia Oncology Associates, accessed March 31, 2025, https://www.virginiacancer.com/multiple-myeloma/treatment-options/
- Multiple Myeloma Treatments | Drugs & Treatment by Stage, accessed March 31, 2025, https://themmrf.org/diagnosis-and-treatment/treatment-options/
- Treatments for multiple myeloma | Canadian Cancer Society, accessed March 31, 2025, https://cancer.ca/en/cancer-information/cancer-types/multiple-myeloma/treatment
- Survival Rates for Multiple Myeloma | American Cancer Society, accessed March 31, 2025, https://www.cancer.org/cancer/types/multiple-myeloma/detection-diagnosis-staging/survival-rates.html
- Advances in Multiple Myeloma Research - NCI, accessed March 31, 2025, https://www.cancer.gov/types/myeloma/research
- Darzalex Faspro, Sarclisa Approvals for Multiple Myeloma - NCI, accessed March 31, 2025, https://www.cancer.gov/news-events/cancer-currents-blog/2025/fda-daratumumab-isatuximab-newly-diagnosed-myeloma
- Looking Ahead: Major Clinical Advancements in Myeloma From ASH 2024 and What's to Come in 2025 - Cancer Network, accessed March 31, 2025, https://www.cancernetwork.com/view/looking-ahead-major-clinical-advancements-in-myeloma-from-ash-2024-and-what-s-to-come-in-2025
- Insights From Latest Research and Trials Advancing Myeloma Care - Targeted Oncology, accessed March 31, 2025, https://www.targetedonc.com/view/insights-from-latest-research-and-trials-advancing-myeloma-care
- Advancements in Multiple Myeloma Therapies and Operational Insights in Oncology Clinical Trials - Pharmacy Times, accessed March 31, 2025, https://www.pharmacytimes.com/view/advancements-in-multiple-myeloma-therapies-and-operational-insights-in-oncology-clinical-trials
- www.cancersupportcommunity.org, accessed March 31, 2025, https://www.cancersupportcommunity.org/sites/default/files/fsac/10_Tips_for_Living_Well_with_Multiple_Myeloma_Fact_Sheet.pdf
- Self-Care for Myeloma Patients | Int'l Myeloma Fndtn, accessed March 31, 2025, https://www.myeloma.org/blog/self-care-for-myeloma-patients
- Multiple Myeloma Patient Information, Caregiver Resources, accessed March 31, 2025, https://www.myeloma.org/patient-caregiver-information
- www.cancercare.org, accessed March 31, 2025, https://www.cancercare.org/diagnosis/multiple_myeloma#:~:text=Oncology%20social%20workers%20help%20you,Learn%20more%20about%20counseling.
- Multiple Myeloma, Cancer, Information, Resources, accessed March 31, 2025, https://www.cancercare.org/diagnosis/multiple_myeloma
- Multiple myeloma - Care at Mayo Clinic, accessed March 31, 2025, https://www.mayoclinic.org/diseases-conditions/multiple-myeloma/care-at-mayo-clinic/mac-20353386
- Multiple Myeloma: Symptoms, What It Is, Prognosis & Treatment - Cleveland Clinic, accessed March 31, 2025, https://my.clevelandclinic.org/health/diseases/6178-multiple-myeloma
- Myeloma Treatment and Survival Rate | City of Hope, accessed March 31, 2025, https://www.cityofhope.org/clinical-program/myeloma/treatments-survival
- Stage 2 Multiple Myeloma Prognosis: Fear, Hope, and Understanding Survival Rates, accessed March 31, 2025, https://www.mymyelomateam.com/resources/stage-2-multiple-myeloma-prognosis-fear-hope-and-understanding-survival-rates
